Synairgen Research’s SNG001 inhaled drug, is being tested by the University of Southampton to treat asthma, chronic obstructive pulmonary disease and lower respiratory tract illnesses caused by coronavirus.
Rankings by 
National Ranking
70th
in United KingdomRegional Ranking
339th
in Western EuropeGlobal Ranking
1522nd
worldwide